Click here to receive MS news via e-mail
The Institute for Clinical and Economic Review (ICER) is currently conducting a review of disease-modifying therapies (Treatments) for relapsing-remitting and primary progressive forms of multiple sclerosis. Insurers may use ICER recommendations to develop or change their approved drug lists, which could potentially improve or restrict access to Multiple Sclerosis medications for people living with MS.
To ensure that people living with MS have direct input into their analysis of the use and effectiveness of disease-modifying therapies, the MS Coalition contacted ICER. As you may know, MS Views and News, is an Associate Member of the MS Coalition.
CONTINUE reading a short description by clicking here
MS Views and News
Providing educational information, resources and services for those affected by MS
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews